Nanobiotix Stock (NASDAQ:NBTX)
Previous Close
$3.10
52W Range
$2.76 - $8.96
50D Avg
$3.95
200D Avg
$5.24
Market Cap
$152.17M
Avg Vol (3M)
$25.76K
Beta
1.40
Div Yield
-
NBTX Company Profile
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
NBTX Performance
Peer Comparison
Ticker | Company |
---|---|
CUE | Cue Biopharma, Inc. |
ZVSA | ZyVersa Therapeutics, Inc. |
DRMA | Dermata Therapeutics, Inc. |
CNSP | CNS Pharmaceuticals, Inc. |
TCRX | TScan Therapeutics, Inc. |
ANNX | Annexon, Inc. |
WVE | Wave Life Sciences Ltd. |
IMMX | Immix Biopharma, Inc. |
CYTO | Altamira Therapeutics Ltd. |
TFFP | TFF Pharmaceuticals, Inc. |
INAB | IN8bio, Inc. |
ZURA | Zura Bio Limited |
CGTX | Cognition Therapeutics, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
ENVB | Enveric Biosciences, Inc. |
PALI | Palisade Bio, Inc. |